Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User

Description

List of Tables

[195 Pages Report] The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.

Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.

KEY MARKET STATISTICS
Base Year [2023]	USD 439.83 million
Estimated Year [2024]	USD 493.23 million
Forecast Year [2030]	USD 1,027.44 million
CAGR (%)	12.88%

Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments

Allogeneic stem cell therapy involves the transplantation of stem cells from a donor to another recipient. This therapy is often preferred in conditions for patients with cells unsuitable for therapy, such as in cases with genetic disorders. It also allows for off-the-shelf solutions, leading to rapidness in treatment administration. On the other hand, autologous stem cell therapy uses a patient's stem cells collected from their bone marrow, adipose tissue, and blood. This type of therapy is associated with a lower risk of immune rejection since the cells are derived from the patient's body.

Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing

Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are obtained from adipose tissue, commonly known as body fat. These cells are of significant interest due to their relative ease of access. The extraction of AD-MSCs involves less invasive procedures than other sources and can be done under local anesthesia via liposuction. AD-MSCs are used in various therapeutic approaches because they differentiate into multiple cell types, secrete growth factors, and modulate immune responses. At the same time, bone marrow-derived mesenchymal stem cells (BM-MSCs) are harvested from the bone marrow, typically from the iliac crest of the pelvis. They are among the extensively studied stem cells with known potential to differentiate into bone, cartilage, and adipose tissue. BM-MSCs also have robust immunomodulatory properties, making them prominent candidates for treating autoimmune diseases and supporting engraftment in bone marrow transplantation. While, placental and umbilical cord-derived mesenchymal stem cells (PC-UC-MSCs) are obtained from the placenta and the umbilical cord following childbirth. These cells are non-invasive to collect and have a higher proliferation rate than adult stem cells, such as AD-MSCs and BM-MSCs.

Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas

Stem cells are being explored as a revolutionary option in the treatment of various cardiovascular diseases, including myocardial infarction and congestive heart failure. Procedures utilizing stem cells have the potential to regenerate damaged heart tissue, improve heart function, and stimulate the repair of cardiac cells. In diseases including lupus and rheumatoid arthritis, sclerosis stem cell therapy can modify the disease process and restore immune balance. These cells can modulate T-cell responses and have been used to treat certain autoimmune diseases. For conditions such as osteoarthritis, muscular dystrophy, and other musculoskeletal disorders, stem cell therapy is promising for regenerating cartilage, bone, and muscle tissues. The treatment aims to reduce pain, improve function, and possibly delay or avoid the need for more invasive treatments like joint replacements. Stem cell therapy's potential to treat neurological disorders such as Alzheimer's is its capacity to protect, repair, or replace neurons and glial cells. Stem cells demonstrate a significant capacity to enhance the healing of wounds and injuries. By deploying MSCs in wound care, these cells can promote the regeneration of skin tissue, reduce scarring, and improve healing times. This is particularly relevant for burn victims, patients with diabetic ulcers, or individuals who experience slow wound healing.

End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes

Academic & research centers are crucial in advancing stem cell science and require various stem cell types to propel disease study, medication development, and therapy innovation breakthroughs. These institutions significantly contribute to pioneering studies and serve as a breeding ground for innovation in stem cell applications. On the other hand, ambulatory surgical centers (ASCs) provide a setting for certain types of outpatient stem cell therapies. These centers, less resource-intensive than hospitals, offer a cost-effective alternative for patients and insurers. Hospitals and clinics remain the primary care setting for the administration of stem cell therapies, particularly for more complex and acute medical conditions. The diverse patient population they serve creates a need for a broad range of stem cell therapies, including hematopoietic stem cell transplantation (HSCT) for diseases such as leukemia and lymphoma and various regenerative medicine applications. Biopharmaceutical companies are key players in the development and commercialization of stem cell therapies. They not only purchase stem cells for R&D purposes - working on new drug discoveries and development of regenerative medicine - but also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale. Biopharma's interest in stem cell therapies corresponds with its ongoing search for innovative treatments that offer improved outcomes over existing medicines. Biopharmaceutical companies work on the development and commercialization of stem cell therapies. They purchase stem cells for R&D purposes to on new drug discoveries and the development of regenerative medicine and also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale.

Regional Insights

In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Allogeneic Stem Cell Therapy
- Autologous Stem Cell Therapy

Cell Source
- Adipose Tissue-Derived MSCs
- Bone Marrow-Derived MSCs
- Placental / Umbilical Cord-Derived MSCs

Therapeutic Application
- Cardiovascular Diseases Surgeries
- Inflammatory & Autoimmune Diseases
- Musculoskeletal Disorders
- Neurological Disorders
- Orthopedics & Rheumatoid
- Wounds & Injuries

End-User
- Academic & Research Centers
- Ambulatory Surgical Centers
- Biotechnology & Pharmaceutical Companies
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stem Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?

4. What is the market share of the leading vendors in the Stem Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?

Product Code: MRR-431752EA49AD

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
  - 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
  - 5.1.1.3. Expansion of stem cell therapy centers and clinics
- 5.1.2. Restraints
  - 5.1.2.1. Difficulties associated with performing stem cell therapy
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in stem cell therapy
  - 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
- 5.1.4. Challenges
  - 5.1.4.1. Ethical and safety issues of stem cell-based therapy
5.2. Market Segmentation Analysis
- 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
- 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
- 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
- 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
5.3. Market Trend Analysis
- 5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
- 5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
- 5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Stem Cell Therapy Market, by Type

6.1. Introduction
6.2. Allogeneic Stem Cell Therapy
6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

7.1. Introduction
7.2. Adipose Tissue-Derived MSCs
7.3. Bone Marrow-Derived MSCs
7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

8.1. Introduction
8.2. Cardiovascular Diseases Surgeries
8.3. Inflammatory & Autoimmune Diseases
8.4. Musculoskeletal Disorders
8.5. Neurological Disorders
8.6. Orthopedics & Rheumatoid
8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

9.1. Introduction
9.2. Academic & Research Centers
9.3. Ambulatory Surgical Centers
9.4. Biotechnology & Pharmaceutical Companies
9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
- 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
- 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
- 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
- 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
- 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
- 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
- 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
- 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
- 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
- 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
- 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
- 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
- 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
- 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio